Plain-English translation of NCT06189391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first study testing , a new immunotherapy treatment, in people with B-cell Non-Hodgkin Lymphoma (a type of blood cancer affecting the lymph nodes and organs) that has either come back after treatment or stopped responding to previous treatments. The medication works by helping your immune system recognize and fight cancer cells. Researchers want to learn whether this treatment is safe, what dose works best, and how well it actually helps patients.
Many people with relapsed or treatment-resistant lymphoma don't have good options left — their cancer either comes back or never fully responds to standard treatments. This trial exists to see whether this new immune-boosting approach might offer hope for patients who have run out of effective choices.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through a vein) once per week for 3 weeks, followed by one week off — a pattern that repeats for up to 12 months. Depending on which treatment group you're assigned to, you may receive either a fixed dose or a gradually increasing "step-up" dose. Throughout the trial, you'll have regular visits for blood tests, imaging scans, and checkups to monitor how well the treatment is working and whether you're experiencing any side effects.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China